On Monday, Shares of Bank of America Corporation (NYSE:BAC), gained 0.40% to $17.77.
Bank of America Corporation is up 8.69% in the last 3-month period. Year-to-Date the stock performance stands at -1.99%. The company shares have rallied 16.75% in the past 52 Weeks. On July 22, 2015, the shares registered one year high of $18.48 and one-year low was seen on January 16, 2015 at $14.97. The 50-day moving average is $17.55 and the 200-day moving average is recorded at $16.56.
Bank of America declared it will report third-quarter 2015 financial results on Wednesday, October 14. The results are planned to be released at 7 a.m. ET, followed by an investor presentation at 8:30 a.m. ET.
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), inclined 16.73% to $8.65, during its last trading session.
Achillion Pharmaceuticals stated financial results for the three and six months ended June 30, 2015. For the second quarter of 2015, Achillion stated a net loss of $29.0 million or $0.25 per share, contrast with a net loss of $15.7 million or $0.16 per share for the second quarter of 2014. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2015 were $261.1 million.
During the second quarter, Achillion granted Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion’s HCV assets. Assuming successful development and commercialization, Achillion is eligible to receive up to $905 million in clinical, regulatory and commercialization milestone payments. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen is responsible for all of the development costs within the partnership and all subsequent costs related to commercialization of the HCV assets. On July 1, 2015, Achillion received $225 million from Johnson & Johnson Innovation – JJDC, Inc. following the issuance of 18,367,346 shares of Achillion at a price of $12.25 per share.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
Finally, Novavax, Inc. (NASDAQ:NVAX), ended its last trade with 6.32% gain, and closed at $14.14. 4,360,310 shares of the company’s stock were exchanged. Novavax has a one year low of $3.92 and a one year high of $15.01. The firm has a 50 day moving average of $12.00 and a 200 day moving average of $9.55. The firm’s market capitalization is $3.80 billion.
Novavax declared its financial results for the second quarter and six months ended June 30, 2015.
Financial Results for the Three and Six Months Ended June 30, 2015
Novavax stated a net loss of $20.6 million, or $0.08 per share, for the second quarter of 2015, contrast to a net loss of $17.9 million, or $0.08 per share, for the second quarter of 2014. For the six months ended June 30, 2015, the net loss was $45.0 million, or $0.18 per share, contrast to a net loss of $31.7 million, or $0.15 per share, for the same period in 2014.
Novavax revenue in the second quarter of 2015 raised 69% to $14.0 million, contrast to $8.3 million for the same period in 2014. This enhance results from the recovery of additional costs under the HHS BARDA contract for the settlement of indirect rates for fiscal years 2011 and 2012, resulting in an additional $7.7 million in revenue for the quarter. This enhance in revenue was partially offset by a decrease in revenue resulting from a lower level of development activities under the HHS BARDA contract and our PATH agreement in the second quarter of 2015 as contrast to the same period in 2014.
Novavax, Inc., a clinical-stage vaccine company, focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
